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ABSTRACT 
Purpose: To investigate whether chronic supplementation with a low or moderate dose of 
dietary nitrate (NO3-) reduces submaximal exercise oxygen uptake ( O2) and to assess 
whether or not this is dependent on acute NO3- administration prior to exercise. Methods: 
Following baseline tests, 34 healthy subjects were allocated to receive 3 mmol NO3-, 6 mmol 
NO3- or placebo. Two hours following the first ingestion, and after 7, 28 and 30 days of 
supplementation, subjects completed two moderate-intensity step exercise tests. On days 28 
and 30, subjects in the NO3- groups completed the test 2 h post consumption of a NO3- dose 
(CHR+ACU) and a placebo dose (CHR). Results: Plasma nitrite concentration ([NO2-]) was 
elevated in a dose-dependent manner at 2 h, 7 days and 28-30 days on the CHR+ACU visit. 
Compared to pre-treatment baseline, 6 mmol NO3- reduced the steady-state O2 during 
moderate-intensity exercise by 3% at 2 h (P = 0.06), 7 days and at 28-30 days (both P < 0.05) 
on the CHR+ACU visit, but was unaffected by 3 mmol NO3- at all measurement points. On 
the CHR visit in the 6 mmol group, plasma [NO2-] had returned to pre-treatment baseline, but 
the steady-state O2 remained reduced.  Conclusion: Up to ~4 weeks supplementation with 6 
but not 3 mmol NO3- can reduce submaximal exercise O2. A comparable reduction in 
submaximal exercise O2 following chronic supplementation with 6 mmol NO3- can be 
achieved both with and without the acute ingestion of NO3- and associated elevation of 
plasma [NO2-].  
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Abbreviations: ANOVA, analysis of variance; ATP, adenosine triphosphate; CHR, effect of 
chronic nitrate supplementation alone assessed; CHR + ACU, combined effect of chronic and 
acute nitrate supplementation assessed; GET, gas exchange threshold; NO, nitric oxide; NO2-, 
nitrite; NO3-, nitrate; O2, oxygen; PLA, placebo; Rpm, revolutions per minute; O2, oxygen 
uptake; O2peak, peak oxygen uptake; W, watts; ∆, change. 
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1. Introduction 
Dietary nitrate (NO3-) has been reported to influence several physiological processes via its 
reduction to nitrite (NO2-), and subsequently to the physiological signaling molecule nitric 
oxide (NO) [1–3]. Indeed, acute ingestion (1-3 h) and chronic supplementation (3-15 days) 
with dietary NO3- has been found to increase plasma NO2- concentration [NO2-], and, in some 
studies, to reduce the oxygen (O2) cost of submaximal exercise [4–6] and improve exercise 
tolerance [5–7] in healthy, young adults (see [8] for review). However, the influence of 
different supplementation strategies on the physiological effects of NO3- ingestion is still not 
fully understood.  
 
Whilst a reduction in the O2 cost of submaximal exercise has been reported 1-3 h post 
consumption of 5.2-16.8 mmol NO3- in some studies [6,9,10], reports on the effect of 
ingesting a lower dose (i.e. 4.2 mmol NO3- or below) are ambiguous [6,11]. It has been 
suggested that chronic supplementation with NO3- may represent a more effective 
supplementation strategy [8,10]. Indeed, 3-7 days of NO3- supplementation has been reported 
to improve mitochondrial efficiency [12] and contractile function [13] by altering the 
expression of mitochondrial [12] and contractile [13] proteins in skeletal muscle. These 
structural adaptations are likely to be responsible, in part, for the reduction in submaximal O2 
uptake ( O2) after chronic NO3- supplementation, but would unlikely be manifest within 1-3 
h after the ingestion of a single NO3- bolus. Given this potential benefit of a chronic NO3- 
supplementation period, it may be reasoned that a significant and consistent reduction in 
submaximal exercise O2 could be achieved with a low dose of NO3- if consumed daily for an 
extended period of time. However, the effect of chronic supplementation with a low dose of 
NO3- (i.e. 4.2 mmol or lower) on the O2 cost of submaximal exercise has not yet been 
investigated. Every nutritional supplement has an associated risk-benefit relationship and 
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financial cost. Determining if a low dose of NO3- consumed chronically can elicit beneficial 
physiological effects is therefore important to guide supplementation procedures and ensure 
individuals do not consume more NO3- than is required.  
 
To fully understand the physiological effects of a chronic and acute supplementation strategy, 
it is important to examine the effects of each strategy independently. In all previous studies 
assessing the influence of chronic NO3- supplementation on the physiological responses to 
exercise, subjects have been instructed to consume their final dose of NO3- 1-3 hours prior to 
final exercise testing, to ensure a significant elevation in plasma [NO2-] [e.g. 4,5,7,9]. 
However, this experimental design only allows for the combined chronic and acute effect of 
NO3- ingestion to be investigated. Indeed, it is possible that: a) any chronic adaptions to daily 
NO3- intake would be detectable in the absence of an acute NO3- dose and thus, no significant 
elevation in plasma [NO2-]; and b) any chronic effects of NO3- supplementation may be 
augmented if an acute NO3- dose is consumed. The adoption of an experimental approach in 
which the chronic effects of NO3- exposure can be isolated from those of the acute effects is 
therefore warranted. This will provide important practical information to guide athletes on 
optimal supplementation strategies before competition after a period of chronic NO3- 
supplementation.  
 
The purpose of this study was therefore twofold: firstly, to compare the effects of acute (2 h), 
7 d and ~30 d supplementation, with a low dose (3 mmol) and a moderate dose (6 mmol; 
positive control) of dietary NO3- on the O2 cost of moderate-intensity exercise; and, secondly, 
to compare the effect of ~30 day supplementation on the O2 cost of moderate-intensity 
exercise with and without the acute consumption of NO3- 2 h prior to assessment. To achieve 
the latter, subjects completed an experimental visit on day 28 and 30 of supplementation: on 
6 
 
one visit subjects consumed an acute dose of NO3- 2 h prior to testing (CHR + ACU); and on 
the other visit, exercise was initiated 24 h post consumption of the most recent NO3- dose 
(CHR), allowing plasma [NO2-] to return to pre-NO3- treatment baseline [6]. It was 
hypothesized that: a) supplementation with 3 mmol NO3- and 6 mmol NO3- would result in a 
lower O2 cost of submaximal exercise at 7 d and 28-30 d on the CHR + ACU visit; and, b) 
any effects observed with CHR + ACU would still be present, albeit to a lesser extent, with 
CHR.   
 
2. METHODS 
2.1. Subjects 
Thirty-four healthy, recreationally-active subjects (19 male, mean ± SD age = 21 ± 3 yr, 
stature = 1.74 ± 0.09 m, body mass = 73.5 ± 14.1 kg) volunteered to participate, gave written 
informed consent, and completed this study that was approved by the Institutional Research 
Ethics Committee. All subjects were nonsmokers and none were taking any nutritional 
supplements in the four months preceding the start of the study. Throughout the 
experimentation, subjects were asked to adhere to their normal exercise routine and diet. 
However, subjects were instructed to avoid foods rich in NO3- (such as green leafy vegetables 
and beetroot) and asked to record their diet and exercise in the 48 h preceding the first 
laboratory visit and to repeat this prior to all subsequent visits. Subjects were instructed to 
arrive at the laboratory in a rested and fully hydrated state, at least 2 h postprandial, and to 
avoid strenuous exercise in the 24 h preceding each testing session. Each subject was also 
asked to avoid caffeine and alcohol 6 and 24 h before each test, respectively. In addition, 
subjects were asked to abstain from using antibacterial mouthwash and chewing gum for the 
duration of the study since this inhibits the reduction of NO3- to NO2- in the oral cavity [14]. 
All laboratory visits were scheduled at the same time of day (± 1 h) for each subject. 
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2.2. Pre-treatment tests 
Subjects were required to report to the laboratory on two separate occasions prior to 
beginning 30 days of supplementation with 3 mmol NO3-, 6 mmol NO3-, or placebo (PLA). 
All exercise tests were performed on an electronically-braked cycle ergometer (Lode 
Excalibur Sport, Groningen, The Netherlands). During visit 1, subjects completed a ramp 
incremental exercise test to the limit of tolerance for the determination of peak O2 ( O2peak) 
and gas exchange threshold (GET). The subjects cycled at a constant self-selected pedal rate 
(80-90 rpm), and this pedal rate, along with saddle and handle bar height configuration, was 
recorded and reproduced in subsequent tests. Initially, subjects performed 3 min of baseline 
cycling at 20 W, after which the work rate increased at a rate of 30 W·min-1 in a linear 
fashion until the limit of tolerance. The test was terminated when the pedal rate fell by > 10 
rpm below the chosen pedal rate, despite strong verbal encouragement. The power output 
achieved at the point of exhaustion was recorded as the peak power output (PPO). Pulmonary 
gas exchange was continuously collected breath-by-breath during the incremental tests and 
averaged over consecutive 10-s periods. The O2peak was calculated as the highest 30-s mean 
value attained before the subject’s volitional exhaustion.  The GET was determined as 
described previously [15,16]. The work rate that would require 80 % of the GET (moderate 
exercise) was then calculated, with account taken of the mean response time for O2 during 
ramp exercise (i.e. two-thirds of the ramp rate was deducted from the work rate at GET; 
[17]).  
 
During visit 2, subjects completed a series of PLA-controlled, baseline measurements. All 
subjects were asked to consume a 50 mL dose of PLA containing negligible NO3- (see 
description under Supplementation procedures for further details), 2 h prior to arrival at the 
laboratory. Upon arrival a venous blood sample was obtained for the measurement of plasma 
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[NO3-] and [NO2-]. Subjects then completed two step transitions to moderate-intensity cycling 
at 80 % GET, with each bout separated by 5-min of passive recovery. Each step transition 
was preceded by 3-min of baseline cycling at 20 W and each bout lasted 5 min. Pulmonary 
O2 was measured breath-by-breath throughout the test and averaged over 10-s periods. The 
data from the two moderate-intensity bouts were time aligned and averaged to improve 
signal-to-noise ratio [18]. The O2 cost of moderate-intensity exercise was then calculated. All 
measurements made during this visit were used as pre-treatment baseline data.  
 
2.3. Supplementation procedures 
After these pre-treatment visits, subjects were assigned in a group-matched fashion for 
moderate-intensity end-exercise O2, PPO, GET and O2peak, to receive either ~3 mmol NO3- 
(administered as 9.75 g of dry beetroot extract [PepsiCo, USA] diluted in 50 mL of water), 
~6 mmol NO3- (administered as 19.5 g of dry beetroot extract [PepsiCo, USA] diluted in 50 
mL of water), or a PLA (containing ~0.01 mmol of NO3-, administered as 9.5 g of sucrose 
and red shade coloring [PepsiCo, USA] diluted in 50 mL of water) per day, for 30 days. 
Subject characteristics are provided in Table 1.  
 
Subjects reported to the laboratory on days 1, 7, 28 and 30 of supplementation to complete 
the full experimental protocol from visit 2 (Fig. 1). On supplementation days 1 and 7, 
subjects were asked to consume their 1st and 7th dose of supplement, respectively, 2 h prior to 
arrival at the laboratory. This pre-test consumption time was selected in order to coincide 
with the peak plasma [NO2-]. While we have previously established that peak plasma [NO2-] 
is attained 2 h post beetroot juice consumption [6], it could not be assumed that this time-to-
peak is consistent after consumption of other NO3- containing supplements because the 
kinetics of plasma [NO2-] may be altered by the form in which the NO3- is administered [19]. 
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We therefore undertook a pilot study which indicated that peak plasma [NO2-] occurred at 2 h 
post consumption of the dry beetroot extract (unpublished observation).  On non-
experimental days, each subject was instructed to consume their allocated supplement at their 
test time from visit 2 (± 10 min), such that the subject would consume one dose of 
supplement every 24 h.  
 
To assess the effect of chronic NO3- supplementation on the O2 cost of submaximal exercise 
with and without the acute consumption of NO3- 2 h prior to exercise, a randomised counter-
balanced design was adopted from day 28 of supplementation for subjects in the 3 mmol and 
6 mmol groups (Fig. 1). Two hours prior to arrival on day 28 of supplementation, subjects in 
the 3 mmol and 6 mmol groups were asked to consume either a PLA beverage [i.e. effect of 
chronic NO3- supplementation alone (CHR) was assessed] (3 mmol: n = 6; 6 mmol: n = 6) or 
their allocated NO3--rich beverage [i.e. combined effect of chronic and acute NO3- 
supplementation (CHR + ACU) was assessed] (3 mmol: n = 5; 6 mmol: n = 6). Ten-minutes 
post completion of the test procedures on day 28, subjects in the 3 mmol and 6 mmol group 
who consumed PLA prior to the test, consumed a dose of their allocated NO3--rich beverage, 
and those that consumed their NO3--rich beverage consumed a PLA beverage. Two hours 
prior to arrival at the laboratory on day 30, subjects consumed the opposite beverage to that 
consumed prior to their laboratory visit on day 28 [e.g. if PLA was consumed prior to arrival 
on day 28, then their allocated NO3--rich beverage was consumed prior to arrival on day 30]. 
Therefore, all subjects were assessed for the CHR + ACU and CHR effects of NO3- 
supplementation.  In all cases, subjects in the 3 mmol and 6 mmol groups consumed 3 mmol 
NO3- or 6 mmol NO3-, respectively, per day. Subjects in the PLA group were instructed to 
continue their normal supplementation routine and consume one dose of PLA 2 h prior to 
arrival at the laboratory on both day 28 and 30 of supplementation. 
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Subjects in the 3 mmol and 6 mmol groups were deliberately misinformed that the effects of 
two different NO3- supplements on the physiological responses of exercise would be tested 
after different supplementation periods.  Subjects in the PLA group were informed that the 
effect of a NO3- supplement would be tested over different supplementation periods. All 
subjects were asked to not comment on the taste or appearance of the supplements to the 
study investigators. Follow up verbal interviews after completion of the study confirmed that 
subjects were unaware of the actual research hypothesis.  
  
2.4. Measurements and data analysis 
During all exercise tests, pulmonary gas exchange and ventilation were measured breath-by-
breath, with subjects wearing a nose clip and breathing through a low dead space, low-
resistance mouthpiece and impeller turbine assembly (Jaeger Triple V, Hoechberg, 
Germany). The inspired and expired gas volume and gas concentration signals were 
continuously sampled at 100 Hz, the latter using paramagnetic (O2) and infrared (CO2) 
analyzers (Jaeger Oxycon Pro, Hoechberg, Germany) via a capillary line connected to the 
mouthpiece. The gas analyzers were calibrated before each test with gases of known 
concentration, and the turbine volume transducer was calibrated with a 3-liter syringe (Hans 
Rudolph, Kansas City, MO). Pulmonary gas exchange and ventilation were calculated and 
displayed breath-by-breath.  
 
The breath-by-breath gas exchange data collected during the two identical, moderate-
intensity step tests performed at pre-treatment baseline on visit 2 and on days 1, 7, 28 and 30 
of supplementation, were averaged over 10-s periods, and time aligned to the start of exercise 
and ensemble-averaged. The end-exercise O2 was defined as the mean value measured over 
the final 60 s of exercise.  
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Venous blood samples were drawn into lithium-heparin vacutainers (7.5 ml Monovette 
lithium heparin; Sarstedt, Leicester, UK). Within 1 min of collection, samples were 
centrifuged at 4,000 rpm and 4 °C for 8 min. Plasma was extracted and immediately frozen at 
-80 °C for later analysis of [NO3-] and [NO2-] as previously described [6]. 
 
Capillary blood samples were collected from a fingertip into a capillary tube during the 20 s 
preceding each step transition in work rate and within the final 20 s of each moderate-
intensity bout. These samples were subsequently stored on ice and analyzed to determine 
blood [lactate] (YSI 1500, Yellow Springs Instruments, Yellow Springs, OH), within 5 min 
of collection.   
 
2.5. Statistical analysis 
A mixed-model ANOVA was used to assess differences in change from pre-treatment 
baseline, in all variables across treatment (PLA, 3 mmol NO3- and 6 mmol NO3-) and time (2 
h and 7 d, and the CHR + ACU visit on day 28 or 30 of supplementation). Differences over 
time within each group were analyzed by a single factor repeated-measures ANOVA. Before 
these analyses, all data collected on days 28 and 30 of supplementation in the PLA group 
were averaged together to form one data point at days 28 and 30 of supplementation. The 
effect of CHR on all variables in 3 mmol and 6 mmol was analyzed separately using a single 
factor repeated measures (pre-treatment baseline, CHR and CHR + ACU) ANOVA. In all 
cases, significant effects were further explored using simple contrasts. All data analyses were 
performed using the SPSS (version 22; SPSS, Chicago, IL) statistical package, with statistical 
significance accepted at P<0.05. Results are presented as mean ± SD unless stated otherwise.  
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3. RESULTS 
Self-reported compliance to the supplementation regime was 100 % in all treatment groups. 
Subjects reported that their diet and exercise habits prior to each experimental test were 
consistent.  
 
3.1. Plasma [NO3-] and [NO2-] 
Plasma [NO3-] and [NO2-] responses in PLA, 3 mmol and 6 mmol groups are presented in 
Figures 2 and 3.  
 
3.1.1. 2 h, 7 d and 28-30 day (CHR + ACU) 
At pre-treatment baseline, plasma [NO3-] was not significantly different between treatment 
groups (PLA: 33 ± 11 μM; 3 mmol: 46 ± 24 μM; 6 mmol: 36 ± 11 μM: P > 0.05).  The 
change in plasma [NO3-] from pre-treatment baseline at 2 h, 7 d and on the CHR + ACU visit 
after 28-30 d is shown in Fig. 2A. Plasma [NO3-] was significantly elevated above pre-
treatment baseline and PLA at all time points in the 3 mmol and 6 mmol groups (all P < 0.05; 
Fig. 2A). The elevation in plasma [NO3-] above pre-treatment baseline in the 6 mmol group 
was greater than in the 3 mmol group at all time points (all P < 0.05; Fig. 2A). The mean 
increase in plasma [NO3-] from pre-treatment baseline, in the 3 mmol and 6 mmol groups 
across the three sample points was 313% and 867%, respectively (3 mmol: 144 ± 23 μM; 6 
mmol: 312 ± 68 μM; both P < 0.05; Fig. 2A). No changes in plasma [NO3-] were observed in 
the PLA group at any time point (all P > 0.05). The rise in plasma [NO3-] from pre-treatment 
baseline was not significantly different between the three sampling time points within any 
treatment group (all P > 0.05).   
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At pre-treatment baseline, plasma [NO2-] was not significantly different between treatment 
groups (PLA: 43 ± 19 nM; 3 mmol: 80 ± 69 nM; 6 mmol: 48 ± 22 nM: P > 0.05). The change 
in plasma [NO2-] from pre-treatment baseline at 2 h, 7 d and on the CHR + ACU after 28-30 
d is shown in Fig. 2B. In the 3 mmol and 6 mmol groups, plasma [NO2-] was significantly 
elevated at all time points (all P < 0.05; Fig. 2B), relative to pre-treatment baseline and PLA. 
In addition, the rise in plasma [NO2-] was greater in the 6 mmol group than in the 3 mmol 
group at all time points (all P < 0.05; Fig. 2B). Across the three sample points, plasma [NO2-] 
rose by 165% and 579%, above pre-treatment baseline, in the 3 mmol (132 ± 49 nM) and 6 
mmol (278 ± 155 nM; all P < 0.05; Fig. 2B) groups, respectively. No changes in plasma 
[NO2-] were observed in the PLA group at any time point (all P > 0.05). The rise in plasma 
[NO2-] from pre-treatment baseline was not significantly different between the three sampling 
time points within any treatment group (all P > 0.05).   
 
3.1.2. Comparison between chronic and chronic + acute supplementation 
The change in plasma [NO3-] from pre-treatment baseline was significantly lower on the 
CHR visit compared to the CHR + ACU visit in both the 3 mmol and 6 mmol groups (P < 
0.05; Fig. 3A). In the 3 mmol group, plasma [NO3-] had returned to pre-treatment baseline on 
the CHR visit (P > 0.05; Fig. 3A). In the 6 mmol group, the plasma [NO3-] remained elevated 
above pre-treatment baseline by 34 ± 36 μM (P < 0.05; Fig. 3A) on the CHR visit.   
 
The change in plasma [NO2-] from pre-treatment baseline was significantly lower on the 
CHR visit compared to CHR + ACU visit in the 3 mmol and 6 mmol groups (P < 0.05; Fig. 
3B). Plasma [NO2-] had returned to pre-treatment baseline on the CHR visit in both the 3 
mmol and 6 mmol groups (P > 0.05; Fig. 3B) 
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3.2. Moderate-Intensity Exercise 
At pre-treatment baseline, the O2 measured over the final 60-s of moderate intensity exercise 
was not significantly different between treatment groups (PLA: 1.46 ± 0.32 L·min-1; 3 mmol: 
1.44 ± 0.23 L·min-1; 6 mmol: 1.44 ± 0.30 L·min-1: P > 0.05).  
 
3.2.1. 2 h, 7 d and 28-30 day (CHR + ACU) 
The change in end-exercise O2 from pre-treatment baseline at 2 h, 7 d and on the CHR + 
ACU visit after 28-30 d is shown in Fig. 4A. In the 3 mmol and PLA groups, end-exercise 
O2 was not significantly different from pre-treatment baseline at any time point (all P > 0.05; 
Fig. 4A). Compared to pre-treatment baseline, end-exercise O2 was significantly reduced in 
the 6 mmol NO3- group at 7 d (by ~3%; 0.04 ± 0.05 L·min-1) and 28-30 d on the CHR + ACU 
visit (by ~3%; 0.04 ± 0.04 L·min-1; both P < 0.05; Fig. 4A), and tended to be reduced at 2 h 
(by ~3%; 0.04 ± 0.02 L·min-1; P = 0.06; Fig. 4A). Compared to PLA, end-exercise O2 was 
significantly reduced in the 6 mmol group at 28-30 d on the CHR + ACU visit (P < 0.05; Fig. 
4A) and tended to be reduced at 7 d (P = 0.08; Fig. 4A). Compared to pre-treatment baseline 
and PLA, baseline, end-exercise and change in blood [lactate] were not altered by 3 mmol or 
6 mmol NO3- at 2 h, 7 d or 28-30 d on the CHR + ACU visit (P > 0.05).  
 
3.2.2. Comparison between chronic and chronic + acute supplementation 
In the 3 mmol group, end-exercise O2 was not different from pre-treatment baseline at 28-30 
d on either the CHR or CHR + ACU visits (P > 0.05). In the 6 mmol group, end-exercise O2 
was significantly lower than pre-treatment baseline at 28-30 days on the CHR visit (by 
~3.5%; 0.05 ± 0.06 L·min-1; P < 0.05; Fig. 4B). This reduction in end-exercise O2 was not 
significantly different from that observed on the CHR + ACU visit (P > 0.05; Fig. 4B).  
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4. DISCUSSION 
The principal novel finding of the present study was that neither 7 days nor ~4 weeks of 
supplementation with 3 mmol NO3-, per day, reduced the O2 cost of moderate-intensity cycle 
exercise, despite an increase in plasma [NO3-] and [NO2-] throughout the supplementation 
period. In contrast, the greater rise in plasma [NO3-] and [NO2-] with 6 mmol NO3- was 
associated with a significant reduction in the O2 cost of moderate-intensity cycle exercise 
after 7 days and ~4 weeks of supplementation, and a trend (P = 0.06) for a reduction after 
acute (2 h) ingestion. Interestingly, this reduction in moderate-intensity O2 after ~4 weeks of 
supplementation was still evident when assessed on a separate occasion without the ingestion 
of NO3- 2 h prior to the exercise test and thus, no elevation in plasma [NO2-]. This study is the 
first to demonstrate a lowering of submaximal O2 following chronic NO3- supplementation 
without a significant concomitant increase in systemic [NO2-].  
 
4.1. The influence of 2 h, 7 d and 28-30 d (Chronic + Acute) NO3- supplementation  
4.1.1. Plasma [NO3-] and [NO2-] 
The administration of beetroot extract containing 3 mmol and 6 mmol NO3- was successful in 
dose-dependently elevating plasma [NO3-] and [NO2-], a finding consistent with that observed 
after the ingestion of concentrated NO3--rich beetroot juice [6] and pharmaceutical NO3- salt 
[20]. In both the 3 mmol and 6 mmol groups, there was no further increase in plasma [NO3-] 
or [NO2-] after 7 days or 28-30 days supplementation (when an acute bolus of NO3- was 
consumed 2 h prior to assessment), compared to the acute ingestion of a single bolus of NO3- 
on day 1. This finding is also in line with previous observations [9,21].  
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4.1.2. O2 cost of submaximal exercise  
In the present study we found that the steady-state O2 measured over the final 60 s of 
moderate-intensity cycle exercise was unaffected by the acute ingestion of 3 mmol NO3- but 
tended (P = 0.06) to be lower by 3% following acute ingestion of 6 mmol NO3-. Several 
previous studies have also reported a dose-response relationship, with higher but not lower 
doses of dietary NO3- eliciting physiological effects [6,22,23]. In particular, we have 
previously reported that the O2 cost of submaximal cycling was unaffected by the acute 
administration of 4.2 mmol NO3-, tended to be reduced (by 1.7%) following administration of 
8.4 mmol NO3-, and was significantly reduced (by 3%) following administration of 16.8 
mmol NO3-, administered in the form of concentrated beetroot juice [6]. The reason for the 
greater relative reduction in submaximal exercise O2  for a given NO3- dose in the present 
study (i.e. 3% reduction with 6 mmol NO3-) compared to that reported by us previously (i.e. 
1.7% reduction with 8.4 mmol NO3-) [6] is unclear. However, despite this, the results 
presented herein and by us previously [6] support a dose-dependent effect of acute NO3- 
ingestion on submaximal exercise O2, and suggest that higher doses of NO3- (≥ 6 mmol 
NO3-) are required to acutely lower the O2 cost of submaximal exercise.   
 
This is the first study to investigate the effect of chronic supplementation with a low dose of 
NO3- on the O2 cost of moderate-intensity exercise. Contrary to our experimental hypothesis, 
we found that prolonging the supplementation period with 3 mmol NO3- to 7 days, and 
further to ~4 weeks, did not lower the O2 cost of submaximal cycle exercise. These results 
suggest that a reduction in submaximal exercise O2 cannot be achieved with a low dose of 
NO3- even with an extension of the supplementation period. In contrast, we found that the O2 
cost of submaximal exercise was significantly lower than pre-treatment baseline after both 7 
days and ~4 weeks of supplementation with 6 mmol NO3-. These findings are in agreement 
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with the 3-6% reduction in the O2 cost of submaximal exercise reported in untrained subjects 
following 3-15 days of supplementation with 5-8 mmol NO3- [4,5,9,12,24]. Therefore, these 
results indicate that the daily ingestion of 6 mmol NO3- reduces the O2 cost of submaximal 
exercise after short duration (7 day) supplementation, and that this effect is maintained over 
~4 weeks of continued supplementation with no evidence of a reduced sensitivity to 
supplementation.  
 
The lowering of submaximal exercise O2 may be a result of improved mitochondrial 
efficiency [12,25, cf. 26] and/or a reduction in the ATP cost of skeletal muscle force 
production [27]. Alterations in the expression, and therefore content, of mitochondrial [12] 
and contractile proteins [13] have been proposed as the mechanistic bases for these effects. 
However, alterations in protein expression are unlikely to occur within 1-3 h of acute NO3- 
ingestion, and can therefore only contribute to a reduction in submaximal exercise O2 after a 
period of chronic NO3- supplementation. Instead, a reduction in O2 following acute NO3- 
ingestion may be related to an acute and reversible change in protein function through post-
translational protein modifications [28]. Given the potential for the protein expression 
changes to occur after chronic supplementation but not acute ingestion, we hypothesized that 
the prolonged exposure to elevated concentrations of NO2- provided by a chronic 
supplementation regime may reduce the dose of NO3- required to lower submaximal exercise 
O2. In contrast to this hypothesis we found that extending the duration of supplementation on 
a low dose of NO3- to ~4 weeks did not result in a reduction in submaximal exercise O2. 
This observation implies that these structural modifications are not only dependent on the 
duration of exposure but also the magnitude of the exposure. The influence of different NO3- 
doses and durations of supplementation on structural modifications to skeletal muscle 
warrants further investigation.     
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4.2. The effect of chronic NO3- supplementation in the absence of acute NO3- ingestion 
 
In all previous studies examining the effect of chronic NO3- supplementation on the 
physiological responses to exercise, subjects have been instructed to consume their final dose 
of NO3- 1–3 h prior to testing [e.g. 4,5,9,12,27,29]. This experimental approach has been 
adopted to ensure a significant elevation in plasma [NO2-] (and therefore the potential for O2-
independent NO synthesis) at the time of assessment. However, considering that: 1) for a 
given dose, the rise in plasma [NO2-] afforded by this chronic supplementation strategy is not 
different to that afforded by a single acute bolus of NO3- [9,21]; 2) acute NO3- 
supplementation may reduce submaximal exercise O2 and improve exercise tolerance [6]; 
and 3) the acute effects of NO3- are believed to be mediated via an elevation in plasma [NO2-] 
[6,9]; it is not possible to fully ascertain if the effects observed after chronic 
NO3- supplementation would still be evident when an acute NO3- dose is not administered.  
Therefore, in the present study, we examined the effects of chronic NO3- supplementation 
both with and without administration of an acute NO3- dose. Specifically, subjects were asked 
to consume their final dose of NO3- 24 h prior to exercise testing. Importantly, 24 h provided 
sufficient time for plasma [NO2-] to return to pre-treatment baseline, a finding that is in 
agreement with the pharmacokinetics of plasma [NO2-] following acute ingestion of similar 
NO3- doses [6,20].  
 
An original finding of the present study was that moderate-intensity steady-state O2 was 
significantly lowered following ~4 weeks of supplementation with 6 mmol NO3-, even when 
24 h had elapsed since the ingestion of the last NO3- dose. To our knowledge, these results 
are the first to demonstrate a reduction in submaximal exercise O2 following NO3- 
supplementation in the absence of an increase in plasma [NO2-]. However, this observation is 
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consistent with a previous report that the physiological effects of NO3- supplementation can 
be achieved without an accompanying rise in plasma [NO2-] [30]. Specifically, Ferguson et 
al., [30] showed that despite no increase in plasma [NO2-] after 5 days of NO3- 
supplementation in rats, microvascular O2 partial pressure was elevated during contraction in 
fast-twitch skeletal muscle. Interestingly, the magnitude of reduction in O2 was not 
significantly different to that observed after ~4 weeks of supplementation when an acute 
bolus of NO3- was consumed prior to testing. These results therefore suggest that following 
chronic supplementation with 6 mmol NO3-, a reduction in the O2 cost of submaximal 
exercise may be preserved up to at least 24 h after the final dose of NO3- is ingested, and that 
the addition of an acute NO3- dose, and the resulting elevation in plasma [NO2-], does not 
augment the reduction in submaximal exercise O2.  The mechanistic basis for this preserved 
reduction in O2 is currently unclear. However, as briefly discussed earlier, the reduction in 
submaximal O2 following chronic NO3- supplementation may be mediated, in part, by a 
change in the content of mitochondrial [12, cf 26] and contractile [13]  proteins, and an 
associated improvement in mitochondrial [12, cf. 26] and contractile [13,27] efficiency. It is 
likely that such structural adaptations are maintained for some period of time after NO3- 
supplementation is stopped, resulting in the preserved reduction in steady-state O2. Indeed, 
the increased expression of mitochondrial proteins following sprint interval training have 
been observed up to 6 weeks after training was ceased [31].  
 
Another possible explanation for the preserved reduction in steady-state O2 is that other 
reactive nitrogen intermediates and/or NO bioavailability remained elevated post NO3- 
supplementation, despite plasma [NO2-] returning to pre-treatment baseline. Previous 
research in rodents has shown that skeletal muscle tissue acts as an endogenous NO2- and 
NO3- reservoir [32] and that NO2- infusion increases the concentration of NO2- in heart, liver 
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and kidney tissue [33]. If this uptake is also true for human skeletal muscle following NO3- 
supplementation, it is possible that the pharmacokinetics of these changes are different to that 
of plasma [NO2-] and [NO3-], and as a result, tissue NO2- may accumulate and remain 
elevated beyond 24 h after the cessation of NO3- supplementation. An increase in tissue NO 
bioavailability may contribute to the reduction in O2 via acutely and reversibly impacting 
mitochondrial and/or contractile protein function through post-translational protein 
modifications [28]. The preserved lowering of O2 in the present study may therefore reflect a 
structural adaptation and/or elevated NO bioavailability in skeletal muscle tissue following 
~4 weeks of supplementation with 6 mmol NO3-. Further research is required to determine 
how long the reduction in submaximal exercise O2 may be preserved following cessation of 
NO3- supplementation.  
 
It should be noted that although the acute elevation of plasma [NO2-] following chronic NO3- 
supplementation did not augment the reduction in moderate-intensity O2 in the present 
study, there are other potential benefits of the systemic rise in plasma [NO2-] resulting from 
the ingestion of an acute bolus of NO3-. Recent evidence suggests that NO3- ingestion 
significantly improves the perfusion and oxygenation of skeletal muscle, particularly type II 
muscle fibers, during exercise [30,34]. The vascular effects of NO3- consumption are believed 
to be mediated acutely by NO2- or its reduction to the potent vasodilator NO [35,36]. Indeed, 
an increase in blood flow to exercising forearm muscle has been reported following acute 
NO2- infusion [37]. Moreover, the acute increase in plasma [NO2-] following acute NO3- 
ingestion has been closely coupled to a reduction in blood pressure, with both returning back 
to pre-treatment baseline values simultaneously at 24 h [6,20]. Collectively, these results 
suggest that improvements in perfusion and oxygenation following NO3- intake would not be 
preserved once NO3- supplementation is ceased and plasma [NO2-] returns back to baseline.  
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If this is the case, an acute dose of dietary NO3- following chronic supplementation may be 
beneficial before exercise in which improved oxygenation and perfusion in type II muscle 
fibers may be advantageous, i.e. high-intensity continuous and intermittent exercise. 
However, it must be acknowledged that a preserved improvement in vascular function could 
be possible if chronic NO3- supplementation results in a greater storage of tissue NO2- (as 
discussed above) and this tissue NO2- is released into the circulation during exercise [32]. 
Therefore, further research is required to determine if any improvement in high-intensity 
exercise performance following chronic NO3- supplementation is preserved after 
supplementation is stopped and plasma [NO2-] returns to baseline. In the present study, we 
focused on the effects of NO3- on submaximal exercise O2 and did not address possible 
changes in exercise performance.  
 
In conclusion, low dose (3 mmol) NO3- supplementation does not significantly reduce the O2 
cost of submaximal cycle exercise acutely, or when the supplementation period is extended to 
~4 weeks, despite a significant elevation in plasma [NO3-] and [NO2-] throughout the 
supplementation period. In contrast, the greater elevation in plasma [NO3-] and [NO2-] 
following 6 mmol NO3- supplementation was accompanied by a reduction in the O2 cost of 
submaximal cycle exercise after 2 h (P = 0.06), 7 days and ~4 weeks (both P < 0.05) of 
supplementation. The present study also demonstrated that the reduction in submaximal 
exercise O2 after ~4 weeks supplementation with 6 mmol NO3- is preserved up to 24 h after 
the latest dose of NO3- is ingested and thus, in the absence of elevated plasma [NO2-]. To our 
knowledge, this study is the first to dissociate the reduction in submaximal exercise O2 from 
an increase in plasma  [NO2-] following NO3- supplementation. This novel observation 
implies that beneficial structural skeletal muscle adaptations had occurred and were 
preserved, and/or muscle [NO2-] remained elevated following chronic NO3- supplementation.  
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Figure Legends 
 
Fig. 1. Schematic illustration of the study design. Following pre-treatment tests, all subjects 
were allocated to receive 6 mmol NO3-, 3 mmol NO3- or placebo for 28 – 30 days. All 
subjects completed two moderate-intensity bouts of cycle, 2 h post-ingestion (day 1; acute), 
and after 7, 28 and 30 days of supplementation. In the 3 mmol and 6 mmol NO3- groups, 
subjects were randomised to receive a dose of placebo or NO3- 2 h prior to exercise testing in 
a counterbalanced order on days 28 and 30 of supplementation. This design enabled the 
efficacy of chronic NO3- supplementation in the absence and presence of an acute NO3- dose 
on the day of exercise testing to be determined. See main text for more details.  
 
 Fig. 2. Change (∆) relative to pre-treatment baseline in plasma [NO3-] (panel A) and [NO2-] 
(panel B) following acute (2 h), 7 d and 28-30 d (CHR + ACU) supplementation with 6 
mmol NO3- (squares), 3 mmol NO3- (triangles) and placebo (circles). Values are mean ± SE. * 
significant difference from pre-treatment baseline (P < 0.05); # significant difference from 
placebo group (P < 0.05); ¥ significant difference from placebo and 3 mmol NO3- group (P < 
0.05)  
  
Fig. 3. Change (∆) relative to pre-treatment baseline in plasma [NO3-] (panel A) and [NO2-] 
(panel B) following 28 – 30 d supplementation with 6 mmol NO3- (squares) and 3 mmol 
NO3- (triangles) when subjects consumed an acute dose of NO3- (CHR + ACU) or placebo 
(CHR) 2 h prior to assessment. Values are mean ± SE. * significant difference from pre-
treatment baseline (P < 0.05).  
 
Fig. 4. The effect of NO3- supplementation on end-exercise O2 during moderate-intensity 
cycle. Panel A: Change (∆) relative to pre-treatment baseline in end-exercise O2 following 
acute (2 h), 7 d and 28-30 d (chronic + acute) supplementation with 6 mmol NO3- (squares), 
3 mmol NO3- (triangles) and placebo (circles). Panel B: Change (∆) relative to pre-treatment 
baseline in end-exercise O2 following 28 – 30-days supplementation with 6 mmol NO3- 
(squares) and 3 mmol NO3- (triangles) when subjects consumed a dose of NO3- (CHR + 
ACU) or placebo (CHR) 2 h prior to assessment. Values are mean ± SE. O2, oxygen uptake. 
* Significant difference from pre-treatment baseline (P < 0.05); ₮ trend towards difference 
from pre-treatment baseline (P < 0.10); # significant difference from placebo group (P <  
0.05); ¥ trend towards difference from placebo group (P < 0.10).  
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Table 1. Subject characteristics. Data expressed as mean ± SD.  
 PLA 3 mmol NO3- 6 mmol NO3- 
    
 n 11 (7 male) 11 (6 male) 12 (6 male) 
Age (yr) 21 ± 4 21 ± 2 22 ± 3 
Weight (kg) 75.9 ± 20.4 74.4 ± 9.8 70.5 ± 10.4 
Height (m) 1.74 ± 0.11 1.73 ± 0.08 1.75 ± 0.09 
